Belkin Announces Mobile Charging Accessories That Are Made-to-Move and New Ways to Protect and Connect Devices
5.9.2024 11:00:00 EEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced 11 new travel-ready products across its mobile charging category, as well as solutions to enable more flexible options to work while on the go. Designed in California at its in-house labs, the new announcements underscore Belkin innovation, quality and its commitment to building products consumers need. All new products are made with post-consumer recycled (PCR) plastics in line with the company’s commitment to find more responsible ways to build products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905171274/en/
Belkin announces new BoostCharge collection at IFA 2024 (Photo: Business Wire)
Belkin International can be found on the IFA show floor, Exhibit Hall 3.2, stand #210.
Foldable Wireless Chargers with Qi2
BoostCharge Magnetic Foldable Charger
This folding stand design is compact and travel ready. Delivering 15W of fast wireless charging to iPhone and other Qi2 enabled devices, its powerful magnetic connection secures the device to charging stand and magnetically holds it vertically or horizontally for hands-free use. Use the elevated, customizable position to scroll or watch, and support the Standby Mode feature for iPhone users. It is available in two versions: standalone charges phone only; the 2-in-1 version charges phone and earbuds. 20W power supply and USB-C cable are included. Premium materials include soft touch phone pad, non-slip base and durable hinge construction.
Price: $44.99 / £39.99 / €44.99 to $69.99 / £59.99 / €69.99
Availability: Standalone version coming September 2024; 2-in-1 version available now at belkin.com and available from Autumn 2024 in select retailers worldwide.
BoostCharge 3-in-1 Magnetic Foldable Charger
Charge all your essentials with this foldable 3-in-1. Both portable and with customizable charging angles, it delivers 15W of fast wireless charging to iPhone or Qi2 enabled device, 5W to Apple Watch and 5W for earbuds. If used as a pad, keep it flat. If a stand is preferred, the pad lifts easily and holds steady. Simply fold it down for safe transport when it’s time to pack it away.
Price: $99.99 / £99.99 / €99.99
Availability: Available now at belkin.com and select retailers worldwide.
BoostCharge Pro Magnetic Wireless Travel Pad
A traveller’s best friend. Available in both 2-in-1 and 3-in-1 versions, use it as a pad or fold up into a stand. It delivers 15W of fast wireless charging to iPhone or Qi2 enabled device, 5W to Apple Watch and 5W for earbuds. Qi2 magnetic technology means the phone is held secure, optimizing energy usage and safeguarding the device's battery life.
Price: $119.00 / £109.00 / €119.00 to $129.99 / £119.99 / €129.99
Availability: Coming Autumn 2024 to belkin.com and select retailers worldwide.
High-capacityPower Banks
BoostCharge Power Bank 10K w/ Integrated Cable
This compact 10K power bank makes charging easy. With integrated PD PPS, charge a USB-C smartphone, earbuds or tablet. It provides the option to split the power and charge multiple devices at once. Available in Black, Blue and Pink and White (MEA exclusive).
Price: $39.99 / £24.99 / €29.99
Availability: Coming Autumn 2024 to belkin.com and select retailers worldwide.
BoostCharge Pro 3-Port Laptop Power Bank 20K
This 65W power bank is built with a 20K battery capacity; enough to charge a laptop, MacBook or smartphone quickly and safely. Its full colour digital display shows battery status to easily monitor the remaining charge and manage power needs efficiently for all devices. Options for 65W PD via single USB-C connection or split the power across two USB-Cs and a USB-A, to charge 3 devices simultaneously.
Price: $89.99 / £79.99 / €89.99
Availability: Available now at belkin.com and belkin.com/uk, and coming soon to select retailers worldwide.
Cables Made More Responsibly
BoostCharge 2-in-1 USB-C and Lightning Cable
Charge existing and future devices with this 2-in-1 cable. MFi and USB-IF certified and tested to over 30,000 bends and over 10,000 plug-ins, this cable will deliver up to 60W of power to any USB-C or Lightning device. It features a built-in interchangeable Lightning connector for users to easily switch between their charging needs. A handy cable strap keeps things tidy and protects it from tangles. Exterior braiding is made of 100% post-consumer recycled polyester, certified by the Global Recycled Standard (GRS), cable head and internal jacket are made of 50% GRS-certified post-consumer recycled thermoplastic.
This is part of a rolling change to transition all our PVC and Braided PVC to PCR material.
Price: $24.99 / £19.99 / €24.99
Availability: Coming Autumn 2024 to select retailers worldwide.
Portable Keyboards for Work-on-the-go
Pro Keyboard Case collection
The Belkin Pro Keyboard case makes working from anywhere, easy. The backlit Bluetooth keyboard pairs to iPad to offer the ease of use of an external keyboard with the added defence of a protective cover. The premium faux leather exterior protects the device, while a soft, anti-slip interior protects the screen from scratches. It auto wakes/sleeps when opening/closing, and features a large, click-anywhere trackpad. Its long-lasting battery (between 460mAh – 600mAh) holds charge independently from iPad.
- Everyday Keyboard Case with Cradle for iPad Air 10.9" and iPad Pro 11" £99.99/ €109.99
- Pro Keyboard Case with Magnetic Stand for iPad Air 10.9" and iPad Pro 11"£139.99 / €149.99
- Pro Keyboard Case with Magnetic Stand for iPad Pro 12.9"£189.99 / €199.99
Availability: Available now at belkin.com/uk,belkin.com/de and Belkin EMEA retailers.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905171274/en/
Contacts
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom